Introduction

Microprofit Biotech, as a national high-tech enterprise, consistently pays much attention to manufacture, R&D, marketing and sales of in vitro diagnosis (IVD) products. The official brand of Microprofit Biotech, fluorecare, has dedicated to entire products of point-of-care (POC) tests based on immunofluorescence quantitative assay platform, which are applied to monitor and prognosis of human diseases with comprehensive parameters, including tumor markers, hormone markers, cardiac markers, infection markers and diabetes markers.

Microprofit fluorecare Immunofluorescence Quantitative Platform uses immunochromatographic technology, aiming for the diagnosis of common human diseases. Based on specific antigen-antibody reaction, the triggered fluorescence of the fluorochrome-labeled complexes is collected and automatically calculated. For certain analyte, including serum, plasma, urine or other sample, fluorecare is able to measure the concentration of various biological markers including tumor markers, hormone markers, infection markers, cardiac markers and diabetes markers with excellent accuracy and easy operation.

In Chinese domestic market, Microprofit Biotech provides high-value products and services for the diagnosis of reproductive system disorders. We originally researched and developed the genital tract infection pathogen detection kits (immunofluorescence assay). They have obtained the third accreditation from the China Food and Drug Administration (CFDA). Our detection kits are able to quickly test the infection of GardnerellaVaginalis, Candida Albicans, Trichomonas Vaginalis, Neisseria Gonorrhoeae and Chlamydia Trachomatis. The tests can be accurately completed in a short time without tedious operation. Our kits have been widely used in the domestic top level hospitals especially in which specialized for women and child. Our genital tract infection pathogen detection kits have received unanimous recognition and praise from obstetrics and gynecology experts in China.